ArticleData in brief2026
Panel dataset on the level of biological asset disclosure items in the financial statements of Malaysian plantation companies.
Article in Data in brief, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This data article presents a longitudinal dataset on mandatory biological asset disclosure items reported by plantation companies listed on Bursa Malaysia. The dataset comprises panel data from 41 publicly listed Malaysian plantation firms, covering 533 firm-year observations over the period 2010-2022. Data were manually extracted from publicly available annual reports and biological asset disclosure sections obtained from the Bursa Malaysia website. The dataset includes twelve mandatory presentation and disclosure items derived from IAS 41 and its Malaysian equivalent, MFRS 141, and is structured using a binary coding approach to indicate the presence or absence of each disclosure item. The dataset provides a standardized and reusable resource for examining biological asset reporting practices over time. It can be combined with firm-level financial, governance, or environmental and social disclosure data to support replication studies, longitudinal disclosure analysis, and cross-jurisdictional comparisons of biological asset reporting under international accounting standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.